Psoriasis: Causes, Types, Treatments, and the Hair Loss Connection

What Is Psoriasis and Why Does It Happen?

Psoriasis is an immune-mediated condition in which dysregulated T-helper-17 cells drive keratinocytes to divide roughly 10 times faster than normal, completing a skin cycle in 3 to 5 days instead of the usual 28 to 30 days. That pile-up of immature cells produces the silvery-white scale on an erythematous base that defines a classic plaque. Genetic susceptibility (particularly the HLA-Cw6 allele), environmental triggers, and an abnormal cytokine cascade all contribute.

The core cytokine network involves interleukin-17A (IL-17A), interleukin-23 (IL-23), and tumor necrosis factor-alpha (TNF-alpha). Dendritic cells release IL-23, which primes T-helper-17 cells to secrete IL-17A, and that cytokine drives keratinocyte proliferation and neutrophil recruitment. This mechanistic clarity explains why biologics targeting these pathways produce dramatically higher clearance rates than older systemic agents. Population-based genome-wide association studies have confirmed more than 80 risk loci, with HLA-C*06:02 conferring the strongest susceptibility.

Triggers that can convert genetic predisposition into active disease include streptococcal pharyngitis (the classic trigger for guttate psoriasis), physical trauma (the Koebner phenomenon), certain medications (lithium, beta-blockers, antimalarials), obesity, and psychological stress. A single trigger rarely tells the whole story.

Types of Psoriasis You May Encounter

Psoriasis is not one disease. It presents across at least five clinically distinct subtypes, each with different treatment implications.

Plaque psoriasis (psoriasis vulgaris) accounts for 80 to 90% of all cases. Well-demarcated, erythematous plaques covered by silvery scale appear most often on elbows, knees, the lower back, and the scalp. Plaques may be a few centimeters or may coalesce to cover large body-surface areas.

Guttate psoriasis appears as small (under 1 cm), drop-shaped lesions scattered over the trunk and limbs. It usually follows a streptococcal infection, particularly in children and young adults, and may resolve spontaneously within weeks.

Inverse (flexural) psoriasis involves skin folds such as the axillae, groin, and inframammary regions. Because friction and moisture are constant, scale is minimal and lesions appear smooth and intensely erythematous. Misdiagnosis as candidiasis or intertrigo is common.

Pustular psoriasis presents as sterile pustules on an erythematous base. The generalized form (von Zumbusch) is a medical emergency requiring hospitalization. The localized palmoplantar variant is debilitating but rarely systemic. The IL-36 receptor antagonist spesolimab (Spevigo) received FDA approval in 2022 specifically for generalized pustular psoriasis flares.

Erythrodermic psoriasis covers nearly the entire body surface with confluent erythema and scaling, impairing thermoregulation and the skin barrier. It carries significant mortality risk and almost always requires inpatient management.

Psoriatic arthritis develops in approximately 30% of psoriasis patients, often asymmetrically affecting the distal interphalangeal joints, and may precede, coincide with, or follow skin disease. Early rheumatologic referral matters because joint damage is progressive and largely irreversible once established.

Scalp Psoriasis and Its Effects on Hair

Up to 80% of people with plaque psoriasis experience scalp involvement at some point during their disease course. Scalp psoriasis produces thick, adherent, yellowish-white scale along the hairline and throughout the scalp, frequently extending just beyond the hairline onto the forehead, neck, and ears. The intense itch drives scratching, which itself can worsen scale and trigger secondary bacterial colonization.

Hair loss from scalp psoriasis is usually temporary. The mechanism is primarily traction and breakage from scale buildup and scratching rather than follicular destruction. When active inflammation resolves with treatment, most patients see full regrowth within three to six months. That pattern closely mimics telogen effluvium, the diffuse shedding that follows a physiological stressor, except that psoriasis-related shedding is localized to areas of active disease rather than diffuse.

Severe, long-standing scalp psoriasis can, in rare cases, produce cicatricial (scarring) alopecia if the inflammatory infiltrate extends deep enough to damage the follicular stem-cell niche. This is distinct from the nonscarring shedding seen in the vast majority of patients.

The clinical picture becomes more complex when scalp psoriasis co-occurs with androgenetic alopecia (male or female pattern hair loss) or alopecia areata. Psoriasis and alopecia areata share immune pathways. Both involve T-cell infiltration of the follicle, though alopecia areata specifically targets the follicular immune privilege through IFN-gamma/JAK signaling rather than the IL-17 axis. A patient presenting with patchy scalp hair loss, nail pitting, and erythematous scalp plaques may have both conditions simultaneously, a presentation that requires biopsy to disentangle.

Clinicians at HealthRX evaluate scalp psoriasis patients for concurrent pattern hair loss by examining the distribution of thinning. Pattern hair loss (androgenetic alopecia) follows the Ludwig scale in women and the Hamilton-Norwood scale in men, with miniaturization of follicles predominantly at the crown and mid-scalp in women, or the vertex and frontal hairline in men. Scalp psoriasis, by contrast, causes diffuse or patchy loss that tracks with active plaques rather than following a predetermined anatomical pattern.

FDA-Approved Treatments: From Topicals to Biologics

Treatment selection in psoriasis depends on disease severity, body-surface area involvement, presence of psoriatic arthritis, patient comorbidities, and prior treatment history. The American Academy of Dermatology (AAD) and the National Psoriasis Foundation classify psoriasis as mild (body-surface area under 3%), moderate (3 to 10%), or severe (over 10% or involving hands, feet, face, or genitals in ways that significantly impair function).

Topical Therapies (Mild-to-Moderate Disease)

High-potency topical corticosteroids, most commonly clobetasol propionate 0.05% cream, ointment, or foam, remain first-line for localized plaque psoriasis. They reduce inflammation rapidly but carry risks of skin atrophy, telangiectasias, and HPA-axis suppression with prolonged use, particularly under occlusion or in flexural areas.

Calcipotriene (a vitamin D3 analogue) used in combination with betamethasone dipropionate produces superior clearance to either agent alone. The fixed-dose combination foam (Enstilar) demonstrated 53.3% treatment success at week 4 versus 5.0% for vehicle in a key Phase 3 trial (N=426). See the published data at PubMed.

Tapinarof (Vtama), an aryl hydrocarbon receptor agonist, received FDA approval in 2022 as a steroid-free topical for adults. In the PSOARING 1 and PSOARING 2 trials (combined N=1,025), 35.4% and 40.2% of patients achieved Physician Global Assessment success at week 12, with a remittive effect observed for a mean of 115 days after stopping active treatment. Full trial results are available here.

Phototherapy (Moderate Disease)

Narrowband UVB (NB-UVB) three times weekly for 24 to 36 sessions produces PASI 75 in roughly 60 to 70% of patients. It is safe during pregnancy and is the preferred second-line option when topicals fail in patients who cannot access biologics. Excimer laser (308 nm) targets recalcitrant plaques with higher fluences per session.

Conventional Systemics (Moderate-to-Severe Disease)

Methotrexate at 15 to 25 mg weekly (oral or subcutaneous) has been used for decades. It achieves PASI 75 in approximately 36 to 45% of patients at 16 weeks and remains a first-line systemic in many countries because of cost. Folate supplementation at 1 mg daily reduces gastrointestinal side effects. Liver biopsy thresholds have been replaced by cumulative-dose monitoring and FibroScan assessment per updated AAD guidelines.

Cyclosporine at 2.5 to 5 mg/kg/day produces rapid clearance (PASI 75 in 50 to 70% within 8 to 16 weeks) but is limited to short courses of 12 to 16 weeks because of nephrotoxicity and hypertension risk. It is particularly useful for rapid disease control before transitioning to a biologic.

Acitretin, a systemic retinoid at 25 to 50 mg daily, is especially effective for pustular and erythrodermic forms and for hyperkeratotic palmoplantar disease. Teratogenicity limits its use in women of childbearing potential; a 3-year contraception window is required after discontinuation.

Biologic Therapies (Moderate-to-Severe Disease)

Biologics have redefined the treatment ceiling. PASI 90 (90% clearance) is now achievable in a majority of patients on IL-23 and IL-17 inhibitors.

TNF-alpha inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol) were the first biologic class approved for psoriasis. Adalimumab achieved PASI 75 in 71% of patients at week 16 in the REVEAL trial (N=1,212). REVEAL full data at PubMed. They remain widely used, particularly in patients with concurrent psoriatic arthritis or inflammatory bowel disease.

Ustekinumab (Stelara), an IL-12/23 inhibitor dosed at weeks 0, 4, and then every 12 weeks, produced PASI 75 in 67.5% (45 mg dose) and 66.4% (90 mg dose) of patients at week 12 in PHOENIX 1 (N=766). See PHOENIX 1 at PubMed.

IL-17A inhibitors (secukinumab, ixekizumab) and the IL-17A/F inhibitor bimekizumab have pushed clearance rates higher. Secukinumab 300 mg achieved PASI 90 in 59% of patients at week 16 in ERASURE (N=738). Published ERASURE data here.

IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) currently produce the highest sustained clearance rates with favorable dosing intervals. In UltIMMa-1 (N=507), risankizumab 150 mg (subcutaneous, weeks 0, 4, 16, then every 12 weeks) achieved PASI 90 in 75.3% of patients at week 16 versus 4.9% for placebo (P<0.001). Full UltIMMa-1 data at PubMed.

The AAD-NPF 2020 guidelines state: "For patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy, biologic agents targeting the IL-17 or IL-23 pathways are recommended as they demonstrate superior efficacy and comparable safety to older systemic agents." Full guidelines accessible here.

Small-Molecule Oral Agents

Apremilast (Otezla), a PDE4 inhibitor at 30 mg twice daily, provides a steroid-free oral option without the monitoring burden of methotrexate or cyclosporine. PASI 75 rates are modest at approximately 33% at week 16 (ESTEEM 1, N=844), but it avoids immunosuppression, making it suitable for patients with frequent infections or contraindications to biologics. ESTEEM 1 data at PubMed.

Deucravacitinib (Sotyktu), a selective TYK2 inhibitor approved in 2022, achieved PASI 75 in 53.6% (POETYK-PSO-1, N=666) and 58.7% (POETYK-PSO-2, N=1,020) of patients at week 16, outperforming apremilast without the class-wide warnings associated with broader JAK inhibitors. POETYK-PSO-1 PubMed entry.

Understanding the Hair Loss Overlap

Patients presenting with both a scaling scalp condition and diffuse or patterned hair thinning need a structured diagnostic approach. Four conditions frequently intersect in clinical practice.

Male Pattern Hair Loss (Androgenetic Alopecia)

Male pattern hair loss affects approximately 50% of men by age 50. Dihydrotestosterone (DHT) binds androgen receptors in genetically susceptible follicles, progressively miniaturizing them along the Hamilton-Norwood pattern. First-line pharmacotherapy includes finasteride 1 mg daily (FDA-approved, mean 1.9-inch increase in hair count versus baseline in a 5-year study) and minoxidil 5% topical or 1.25 mg oral. Scalp psoriasis superimposed on male pattern hair loss accelerates apparent thinning because inflamed, scaling skin further stresses already-miniaturizing follicles.

Female Pattern Hair Loss (Androgenetic Alopecia in Women)

Female pattern hair loss follows the Ludwig classification, with diffuse thinning over the crown and preserved frontal hairline. Hormonal contributors include hyperandrogenism from polycystic ovarian syndrome, post-menopausal estrogen decline, and thyroid dysfunction. Minoxidil 2% or 5% topical remains the only FDA-approved topical treatment for women. Low-dose oral minoxidil (0.25 to 1 mg daily) is used off-label with growing evidence supporting efficacy and tolerability. Scalp inflammation from concurrent psoriasis may compound telogen cycling and worsen perceived density.

Telogen Effluvium

Telogen effluvium is the premature mass shift of anagen (growing) follicles into telogen (resting) phase following a physiological stressor, including major illness, surgery, extreme psychological stress, nutritional deficiency, or rapid weight loss. Hair sheds 2 to 4 months after the inciting event, and diffuse shedding typically self-resolves within 6 to 9 months once the stressor is removed. The condition does not damage follicles permanently. Scalp psoriasis can serve as the physiological stressor triggering telogen effluvium, or both conditions can co-occur independently in a patient who has experienced a separate systemic stressor. Trichoscopy showing yellow dots or miniaturized hairs helps distinguish androgenetic alopecia from pure telogen effluvium. Review of telogen effluvium pathophysiology at PubMed.

Alopecia Areata

Alopecia areata is an autoimmune condition in which CD8+ T-cells breach follicular immune privilege, producing discrete, well-demarcated patches of nonscarring hair loss. Unlike scalp psoriasis, alopecia areata plaques show no scale and no erythema; the scalp surface appears entirely normal within patches. Nail pitting appears in up to 66% of alopecia areata patients, the same finding that raises suspicion for psoriasis, making biopsy essential when both are possible. JAK inhibitors (baricitinib 2 mg daily, FDA-approved 2022 for severe alopecia areata; ritlecitinib 50 mg daily, FDA-approved 2023) have transformed treatment outcomes for severe alopecia areata. Baricitinib BRAVE-AA1 and BRAVE-AA2 combined data at PubMed. Psoriasis patients receiving biologic therapy targeting IL-17 pathways may paradoxically develop new-onset alopecia areata, as IL-17 suppression may shift the immune response toward a Th1/Th2 pattern that favors alopecia areata pathology.

Psoriasis Comorbidities Clinicians Must Screen For

Psoriasis is a systemic inflammatory disease. Skin plaques are the visible manifestation of widespread vascular and metabolic inflammation. Patients with moderate-to-severe psoriasis carry a significantly higher risk of myocardial infarction. A 2006 cohort study published in JAMA found that young adults (aged 30 years) with severe psoriasis had a 3-fold higher risk of MI compared to controls (adjusted incidence rate ratio 3.10 to 95% CI 1.98 to 4.86). JAMA 2006 cohort study here.

Screening priorities include lipid panel, fasting glucose/HbA1c, blood pressure, and depression assessment at every annual visit. The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) recommends structured cardiovascular risk calculation using the ACC/AHA Pooled Cohort Equations, treating psoriasis as an independent risk-enhancing condition comparable to chronic kidney disease. ACC/AHA cardiovascular risk guidance at AHA Journals.

Metabolic syndrome occurs in approximately 40% of patients with severe psoriasis, and non-alcoholic fatty liver disease prevalence is elevated, a consideration that affects methotrexate dosing decisions. Inflammatory bowel disease (Crohn's and ulcerative colitis) shares cytokine pathways with psoriasis; approximately 1.6 to 2.0% of psoriasis patients carry an IBD diagnosis, higher than the general population rate of 0.5%.

Practical Treatment Decisions at HealthRX

Selecting therapy at HealthRX starts with a severity classification visit using the PASI and DLQI (Dermatology Life Quality Index). A DLQI score above 10 indicates "very large" quality-of-life impact and qualifies a patient for systemic therapy regardless of body-surface area percentage.

For mild scalp-predominant disease, the default is a combination of calcipotriene/betamethasone dipropionate foam applied nightly for 4 weeks, then reassessment. If scale persists, adding a salicylic acid 6% shampoo twice weekly enhances penetration by removing the physical scale barrier before the active agent contacts skin.

Patients with moderate-to-severe disease who have failed two topicals receive apremilast or deucravacitinib as a bridge while completing insurance prior-authorization for a biologic. The IL-23 inhibitor class (risankizumab or guselkumab) is preferred for new biologic starts in patients without psoriatic arthritis given the high sustained-clearance data and favorable 12-week dosing interval. Patients with active psoriatic arthritis receive an IL-17 inhibitor or a TNF-alpha inhibitor because these agents have demonstrated structural-progression arrest in the joint compartment.

When scalp psoriasis is accompanied by confirmed androgenetic alopecia, minoxidil therapy is not contraindicated. Topical minoxidil 5% solution or foam can be applied to the scalp once the active psoriatic plaques are under control, as minoxidil applied to actively inflamed or broken skin may cause irritation and systemic absorption is unpredictable in that setting.

Dr. Mark Lebwohl, Professor and Chair of Dermatology at Mount Sinai, has stated: "The IL-23 inhibitors represent a step-change in psoriasis management. Patients who previously cycled through multiple treatments are now achieving complete skin clearance and maintaining it for years."

Patients starting a biologic at HealthRX receive baseline tuberculosis screening (QuantiFERON-TB Gold), hepatitis B serology, and a complete blood count. Live vaccines must be administered at least 4 weeks before biologic initiation. Annual influenza and every-5-year pneumococcal vaccines are recommended throughout biologic therapy per CDC guidelines. CDC vaccination guidance for immunocompromised adults.